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Background/aim: The aim of this study was to investigate Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in the
differential diagnosis and prognosis of nonsmall cell lung cancer.
Materials and methods: The expression of Napsin-A, NTRK-1, NTRK-2, and Desmoglein-3 was examined by immunohistochemistry
in 50 squamous cell carcinomas and 50 adenocarcinomas. Desmocollin-3 was investigated in 29 squamous cell carcinoma and 29
adenocarcinoma cases. Associations between expression profiles of Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in
lung cancers and clinicopathological variables were analyzed.
Results: Napsin-A staining was statistically significant in detecting adenocarcinomas versus squamous cell carcinomas. The sensitivity of
Napsin-A for adenocarcinomas was 96% and the specificity was 100%. NTRK-2 and Desmocollin-3 staining were statistically significant
in detecting squamous cell carcinomas versus adenocarcinomas. Desmoglein-3, Napsin-A, and NTRK-2 had no effect on survival.
Disease-free survival time was significantly shorter in cases that were moderately positive with NTRK-1.
Conclusion: Our data suggest that Napsin-A, NTRK-2, and Desmocollin-3 are useful markers in the differentiation of nonsmall cell
lung cancer.
Key words: Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, Desmocollin-3, lung cancer

1. Introduction
Lung cancer is a widely seen disease making up 13% of
all cancers, being responsible for 18% (1.4 million) of
cancer-related deaths (1). It is the major cause of cancerrelated mortalities in both sexes across the world. The
most important reason for high mortality is the diagnosis
being determined at a late stage in 70% of cases, when no
effective treatment is available (2,3). Moreover, resection
in patients who present with an advanced stage of lung
cancer is not appropriate and such patients can only benefit
from chemotherapy. The primary pathological diagnosis
in advanced stage patients, who represent the majority
of the cases, is established through a limited number of
specimens from small biopsies and cytology samples (2).
The four major types of lung cancer are small
cell carcinoma (SCC) and nonsmall cell carcinomas
(NSCLC) including squamous cell carcinoma (SqCC),
adenocarcinoma (AC), and large cell carcinoma (LCC).
Until recently, it was sufficient to distinguish SqCC from
* Correspondence: tedirne@pau.edu.tr
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NSCLC, as management was similar for all subtypes of
NSCLC (4,5). With the development of new biological
agents, accurate distinction between AC and SqCC is
now critical as histological subtyping is important in
clinical decision making (6). In particular, if the tumor
represents a less differentiated or heterogeneous area in
small biopsy and cytological samples, the contribution of
available immunohistochemical markers to a differential
diagnosis becomes even more limited. There is now a
greater obligation on pathologists to accurately subtype
NSCLC in small biopsy specimens with the help of
immunohistochemical and molecular markers (7).
Napsin-A is an aspartic proteinase enclosed in
the cytoplasm of type II pneumocytes and alveolar
macrophages in the lungs and plays a role in the maturation
of surfactant protein-B. Besides the lungs, it is also found
in the kidneys’ proximal tubule and convoluted tubule
epithelia (8). It regulates the absorption and catabolism
of the proteins in the proximal tubules of the kidneys (9).

BİR et al. / Turk J Med Sci
It is a specific marker for pulmonary adenocarcinomas
and for a small portion of papillary-type renal cell and
papillary-type thyroid carcinomas. It is thought to be a
very useful marker when used in combination with TTF-1
in distinguishing between primary adenocarcinomas and
metastatic adenocarcinomas of the lungs (8).
The neurotrophic tyrosine kinase receptors NTRK-1
and NTRK-2 are from the family of neuron growth factor
receptors responsible for neuronal development. They play
a major role in neuronal proliferation and cell survival.
Activation of the NTRK gene in the alveolar cells of the
lungs regulates the survival and proliferation of alveolar
cells. On the other hand, inhibition of NTRK induces
apoptosis and reduces clonogenicity. Strong expressions
of NTRK-1 have been reported in normal epidermis, oral
mucosa, and epidermal carcinomas (basal cell carcinoma
and squamous cell carcinoma). NTRK-2 is found in
normal lung, liver, and heart tissues. Unlike NTRK-1, it
has not been detected in normal epidermis, normal oral
mucosa, basal cell carcinoma, or squamous cell carcinomas
of the skin. NTRK-1 and NTRK-2 have been found to
be expressed more strongely in immunohistochemical
terms in squamous differentiation than in glandular
differentiation. It has been reported that they can be useful
in distinguishing SqCC from AC, especially in small
samples such as needle biopsies that cannot be diagnosed
in histological terms (6,10).
Desmoglein-3 is an adhesion protein of the cadherin
family that is expressed in the stratified squamous
epithelium (3). Desmocollin-3 shows stronger expression
in the basal layers of the stratified squamous epithelium
and is localized in the desmosomal junction of epithelial
cells. It shows weaker expression in the basal layers of
columnar epithelia of trachea and bronchi in the lungs
(11). Desmocollin-3 and Desmoglein-3 are suggested to be
valuable new immunohistochemical markers in squamous
differentiation (3,11).
The aim of the present study was to determine the
role of TTF-1, p63, Napsin-A, NTRK-1, NTRK-2, and
Desmoglein-3 and Desmocollin-3 in the diagnosis of
SqCC and AC of the lung and to investigate the possible
use of these markers in the differential diagnosis and
prognosis of SqCC and subtypes of AC. The sensitivity and
the specificity values of each marker were compared.
2. Materials and methods
We retrospectively investigated 100 cases of pulmonary
carcinoma, 50 being SqCC and 50 AC, which had been
diagnosed at the Pathology Department of Pamukkale
University Faculty of Medicine between 2007 and 2013.
The cancer stages ranged between I and IV and no
chemotherapy was administered to the patients but 58%
underwent lobectomy, 28% pneumonectomy, and 14%

wedge resection. Records from the electronic hospital
data were searched for demographic information, the
tumor’s preoperative phase, types of treatment, durations
of follow-up, and disease outcomes (disease-free survival,
overall survival, relapse, and cancer-related mortality
data). The diagnosis of pulmonary carcinoma in the
histological sections of the resection materials of each
patient, the tumor’s differentiation, and the presence of
metastatic lymph node dissection materials were reviewed
and assessed.
In the histopathological examinations, the SqCC
patients were assessed based on the 2004 classification of
the WHO. The AC cases were reclassified in view of the
guidelines published by IASLC/ATS/ERS collectively in
2011 (12), which are recommended for resection specimens.
Tumor staging was carried out according to the criteria in
the American Joint Committee for Cancer Staging and End
Results Reporting (AJCSS) for 2009 (13,14).
A specimen reflecting the tumor tissue best was chosen
from each case. Five pieces of 3-µm sections were taken
for each case from the chosen paraffin blocks and placed
on positive loaded slides to work on Napsin-A, NTRK-1,
NTRK-2, Desmoglein-3, and Desmocollin-3 antibodies.
Then, with the help of a VENTANA BenchMark LT device,
they were stained automatically using anti-Napsin-A
antibody (clone EPR6252, Abcam, 1/250 dilution),
NTRK-1 antibody (clone 0193R, Bioss, 1/100 dilution),
NTRK-2 antibody (clone 0175R, Bioss, 1/100 dilution),
anti-Desmoglein-3 antibody (clone 6585R, Bioss, 1/100
dilution), anti-Desmocollin-3 antibody (clone EPR7486,
Abcam, 1/50 dilution), p63 (clone 7 JUL, Novocastra,
dilution 1/25), and TTF-1 (clone SP141, Novocastra,
ready-to-use).
Cases were assessed assuming that granular
cytoplasmic staining displays positivity for Napsin-A. The
positive controls of Napsin-A were type II pneumocytes
and alveolar macrophages. Cytoplasmic staining with or
without circumferential membranous involvement was
considered positive for NTRK-1 and NTRK-2. Sporadic
nuclear positivity was also assessed. The skin was used
as the positive control of NTRK-1 and the alveolar
macrophages were used as the positive control for NTRK2. Skin tissue was used as positive control for Desmoglein-3
and Desmocollin-3. Cytoplasmic and nuclear staining
with Desmoglein-3 in varying amounts was considered as
positive. Cytoplasmic staining and marked membranous
staining were considered as positive for Desmocollin-3.
The semiquantitative and subjective grading system
was used for Napsin-A, NTRK-1, NTRK-2, Desmoglein-3,
and Desmocollin-3 to examine the intensity of staining
and the staining rate of tumor cells in 4 categories: 0: no
staining, 1: mild staining, 2: moderate staining, 3: marked
staining.
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The statistical analyses were carried out using SPSS
17.0 for Windows. The Kruskall–Wallis H test was used
to compare the variables between the SqCC and AC
groups, logistic multivariate regression analysis was used
to compare the immunohistochemical staining between
the two groups, and the Kaplan–Meier test was used for
the analysis of survival.
3. Results
The clinical follow-up information was obtained for all
the subjects included in the study. The clinicopathologic
data are summarized in Table 1. Histologically, 50 of
the subjects (50%) showed SqCC and 50 of them (50%)
AC morphology. From those who had AC, 16 (32%) had
papillary, 13 (26%) acinar, 8 (16%) solid, 7 (14%) lepidic,
5 (10%) micropapillary, and 1 (2%) minimal invasive
subtypes of adenocarcinoma. From the SqCC cases, 16
(32%) showed well differentiated, 21 (42%) moderately
differentiated, and 13 (26%) poorly differentiated SqCC
morphology. From the AC cases, 8 (16%) showed well
differentiated, 29 (58%) moderately differentiated, and 13

(26%) poorly differentiated AC morphology. The smallest
tumor diameter was 1 cm and the largest 10 cm, with a
mean diameter of 4.01 ± 2.09 cm. Angiolymphatic invasion
was found in 49 of the tumors (49.0%). Tumors were found
at the bronchial surgery border in 2 (2.3%) of the 84 patients
who underwent lobectomy and pneumonectomy. One of
these patients was in the SqCC group and the other in the
AC group. Pleural involvement evaluation revealed that the
tumor infiltrated the visceral pleura in 15 (15%) patients.
According to the new AJCSS lung cancer staging system
for 2009, the distribution of the cases by their stages was
as follows: in the SqCC group, 8 patients were at Stage IA
(8%), 12 patients at Stage IB (12%), 8 patients at Stage IIA
(8%), 12 patients at Stage IIB (12%), 4 patients at Stage IIIA
(4%), and 6 patients at Stage IV (6%). In the AC group,
15 patients were at Stage IA (15%), 4 patients at Stage IB
(4%), 12 patients at Stage IIA (12%), 5 patients at Stage IIB
(5%), 4 patients at Stage IIIA (4%), and 10 patients at Stage
IV (10%). There was no statistically significant correlation
between the distribution of cases by stages or tumor types
(P > 0.05).

Table 1. Characteristics and clinicopathologic findings of lung cancer cases.
SqCC Number of cases (n)

AC Number of cases (n)

Percent (%)

40–65

33

32

65

>65

17

18

35

Male

50

39

89

Female

0

11

11

Right lung

28

31

59

Left lung

22

19

41

Yes

6

10

16

No

44

40

84

Yes

3

9

12

No

47

41

88

Alive

30

34

64

Exitus

20

16

36

Age

Sex

Localization

Metastasis status

Recurrence status

Survival status

SqCC: squamous cell carcinoma, AC: adenocarcinoma
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All patients in the SqCC group were male; 39 (78%)
of the patients in the AC group were male and 11 (22%)
were female. The difference between tumor type and sex
was statistically significant (P = 0.01). No statistically
significant difference was seen between tumor type and
age groups, the localization of the tumor, bronchial surgery
border, pleural involvement, angiolymphatic invasion,
stage, relapse, distant organ metastasis, or exitus (P > 0.05).
The most sensitive marker was p63 (100%) for SqCC
in all SqCC cases, followed by Desmocollin-3 (96.6%),
Desmoglein-3, and NTRK-2 (both 94%). The most specific
marker for SqCCs was p63 (98%), and then came NTRK-2
(36%) and Desmocollin-3 (34.5%). TTF-1 (100%) was the
most sensitive marker for AC in all AC and SqCC cases;
it was followed by Napsin-A (96%). The most specific
marker for ACs was Napsin-A (100%) and then came
TTF-1 (98%) (Table 2).
We found a statistically significant difference in favor
of adenocarcinoma versus SqCC (P < 0.05) in the analysis
of Napsin-A staining and tumor type. Excluding the solid
type, all other AC subtypes showed marked staining with
Napsin-A. Napsin-A staining in one of the AC cases is
shown in Figure 1a. Napsin-A staining was also positive in
tumor-free areas, type-II pneumocytes, foamy histiocytes,
and some necrotic areas.
In all of the 100 cases, varying degrees of cytoplasmic
staining with NTRK-1 were observed in many areas
although nuclear staining was less frequent. No
relationship between NTRK-1 staining and tumor type
was observed (P > 0.05). Comparison of the degrees of
staining revealed that 14 of SqCCs (28%) showed mild, 15

(30%) moderate, and 21 (42%) marked staining, whereas
6 of the adenocarcinomas (12%) displayed mild, 11 (22%)
moderate, and 33 (66%) marked staining. Comparison of
mildly stained materials with moderately and markedly
stained cases exposed no statistically significant difference
between these two groups in terms of the degree of staining
with NTRK-1 (P > 0.05).
Analysis of NTRK-2 staining and tumor type revealed
a statistically significant difference in detecting SqCC (P <
0.05). NTRK-2 staining in one of the SqCC cases is shown
in Figure 1b. Analysis of Desmoglein-3 staining and tumor
type showed no statistically significant difference (P > 0.05).
Apparent staining in tumor giant cells was remarkable
in addition to positive staining with Desmoglein-3 in
nontumor pulmonary parenchyma, type II pneumocytes,
inflammatory cells, secretions, endothelial cells, and
chondrocytes.
Analysis of Desmocollin-3 staining and tumor type
showed a statistically significant difference in detecting
SqCC (P < 0.05). Desmocollin-3 staining in one of the
SqCC cases is shown in Figure 1c. With Desmocollin-3,
positive staining was seen in some type-II pneumocytes,
alveolar macrophages, bronchial epithelium, endothelial
cells, and in seromucous gland cells in nontumor
pulmonary parenchyma.
Fifty patients in the SqCC group were followed up for
between 2 and 74 months and 20 of them (40%) had died by
the end of the follow-up period. The disease-free survival
time was 46.8 ± 4.5 months for SqCC patients. Patients
in the AC group were followed up for between 1 and 76
months and 16 of them (32%) had died by the end of the

Table 2. Tumor type and expression of markers in lung cancer cases.
SqCC n (%)

AC n (%)

P

TTF-1 (+)
TTF-1 (–)

1 (2)
49 (98)

50 (50)
0 (0)

<0.05

p63 (+)
p63 (–)

50 (50)
0 (0)

1 (2)
49 (98)

<0.05

Napsin-A (+)
Napsin-A (–)

0 (0)
50 (100)

48 (96)
2 (4)

<0.05

NTRK-1 (+)
NTRK-1 (–)

36 (72)
14 (28)

44 (88)
6 (12)

>0.05

NTRK-2 (+)
NTRK-2 (–)

47 (94)
3 (6)

32 (64)
18 (36)

<0.05

Desmoglein (+)
Desmoglein (–)

47 (94)
3 (6)

46 (92)
4 (8)

>0.05

Desmocollin (+)
Desmocollin (–)

28 (96.6)
1 (3.4)

19 (65.5)
10 (34.5)

<0.05

SqCC: squamous cell carcinoma, AC: adenocarcinoma
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follow-up period. The disease-free survival time was 50.1
± 5.2 months for AC patients. The relationship between
tumor type and disease-free survival was statistically
insignificant (P > 0.05).
Analysis of stage and tumor type revealed a mean
survival time of 64.7 ± 3.8 months at stage I, 44.4 ± 5.1
months at stage II, 13.11 ± 3.5 months at stage III, and 27.0
± 4.3 months at stage IV. Being at stage I had a protective
effect independent of other factors (odds ratio = stage I/
stage IV: 0.15 95% confidence interval: 0.04–0.52) and
prolonged survival time. The relationship between tumor
stage and disease-free survival was also statistically
significant (P < 0.05).

407
408

Analysis of immunohistochemical markers and
survival time showed that the relationship between
survival and Napsin-A (P > 0.05), NTRK-2 (P > 0.05),
Desmoglein-3 (P > 0.05), and Desmocollin-3 (P > 0.05)
was statistically insignificant. However, disease-free
survival time was shorter in NTRK-1 moderately stained
cases than in mild stained cases (P > 0.05) (odds ratio
for NTRK-1 moderately positive = 3.7; 95% confidence
interval: 1.3–10.6) (Figure 2).
Apart from this, no significant relationship was found
between survival and tumor type, tumor subtype, tumor
diameter, patient age, sex, tumor localization, lymph node
metastasis, or angiolymphatic invasion.

a

410

Figure 1a. Marked Napsin-A staining in one of the AC cases
(Napsin-A × 100 ihc).
411

Figure 1b. NTRK-2 staining in SqCC (NTRK-2 × 100 ihc). b

Figure 1 b) NTRK-2 staining in SqCC (NTRK-2 x100
Figure 1a) Marked Napsin-A staining in one of the AC cases (Napsin-Ax100 ihc).
412

409

413
414
415
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Figure 1c. Marked Desmoglein-3 positivity in SqCC
c
(Desmoglein-3
100 ihc). Desmoglein-3 positivity in SqCC
Figure 1 c) ×Marked

(Desmoglein-3x100 ihc).
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ntrk1 gr

Cumulative survival

NTRK1 negative
positive
NTRK1 negative-censored
positive-censored

Disease free-survival (months)
Figure 2. Relation between NTRK-1 staining and disease-free survival rate.

4. Discussion
We found that TTF-1 was the most sensitive marker
and Napsin-A the most specific marker in pulmonary
adenocarcinomas, while p63 showed the highest specificity
and sensitivity in SqCC. With respect to sensitivity, p63
was followed by Desmocollin-3 (96.6%) and Desmoglein-3
(94%).
Many studies have shown that Napsin-A
positivity ranges between 58% and 91% in pulmonary
adenocarcinomas (8,15–19). In our study, Napsin-A was
the marker with the highest specificity (100%) and the
second highest sensitivity (96%) after TTF-1. As reported
in many studies in the literature, we also found manifest
Napsin-A negativity for SqCC (20–23).
A study that investigated Napsin-A staining in
bronchioloalveolar carcinomas reported that most of the
cases were Napsin-A positive. In their series of mucinous
and nonmucinous bronchioloalveolar carcinomas,
Napsin-A was more sensitive than TTF-1 (20). In our
study, 8 of the 50 AC cases were lepidic predominant
type (nonmucinous bronchioloalveolar carcinoma as per
2004 WHO) and all of them showed marked staining with
Napsin-A as was the case in the above study. Napsin-A
was reported to show significantly higher positivity
than surfactant protein A in acinar, papillary, and mixed
subtypes of adenocarcinomas (19). We also found higher
degrees of staining with Napsin-A in the acinar and
papillary subtypes, in concordance with this result.
In another study investigating 686 primary pulmonary
cancers, NTRK-1 showed high specificity (92.8%) but
relatively low sensitivity (71.6%) in SqCC (10). In the same
study, NTRK-2 was also found to be specific (96.4%) for

SqCC but with quite low sensitivity (51.3%). The sensitivity
of NTRK-1 for SqCC was 72% and the specificity was 28%
in our study. Our study presents comparable results with
a sensitivity of 94% and a specificity of 6% for NTRK-2
in SqCC cases. Our findings suggest that NTRK-2 can
be a useful marker in showing squamous differentiation.
Zhang et al. studied 60 patients with nonsmall cell
lung cancer with NTRK-2 and reported that NTRK-2
expression was positive in 40 (66.7%) of the patients. A
statistically significant correlation was found in these cases
only between the NTRK-2 expression and the TNM stage
and lymph node metastasis (24). In our study, 94% of the
SqCC cases and 64% of the AC cases were found NTRK2 positive and, in contrast with this study, we observed a
significant difference in favor of SqCC between the NTRK2 expression and the tumor’s histological type.
In a study by Tsuta et al., Desmocollin-3 was found
to be the most sensitive marker (with 100% specificity)
in SqCC (25). We found the specificity of Desmocollin-3
to be quite lower (3.4%) in SqCC, but its sensitivity was
higher (96.6%).
Another study revealed Desmocollin-3 positivity in
nearly a half of the 62 undifferentiated LCC cases and
TTF-1 negativity in all of these cases (11). The authors
concluded that Desmocollin-3 was expressed in a portion
of pulmonary LCC and that these cases were not stained
with TTF-1. They stated that an immunohistochemical
panel including Desmocollin-3 and TTF-1 would assist
in determining morphology in such cases. In accordance
with this, we also found that Desmocollin-3 is a useful
marker in determining squamous differentiation and we
also suggest that Desmocollin-3 should be present in the
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panel when dealing with undifferentiated tumors whose
differential diagnoses cannot be established in small
biopsy and cytology materials.
Fukuoka et al. showed that Desmoglein-3 had 88%
specificity and 98% sensitivity for SqCC compared
with AC. They also found that Desmoglein-3 positivity
was associated with a poor prognosis (26). Cui et al.
reported that Desmocollin-3 was a potential diagnostic
marker for SqCC in primary pulmonary tumors and that
Desmocollin-3 DNA hypermethylation was correlated
with poor prognosis and the Desmocollin-3 gene acted
like a new tumor suppressor gene that inhibits EGFR (27).
We could not report any significant effect on prognosis
with Desmoglein-3.
A study exploring the effect of Napsin-A on prognosis
in pulmonary AC reported that Napsin-A negativity
was an independent prognostic factor reducing patient
survival (28). In our study, 47 of the pulmonary AC cases
were Napsin-A positive. Only 3 cases were not stained
with Napsin-A and since the number of patients was small
in this group, the prognostic significance of Napsin-A
in AC was not studied statistically. When the entire 100
cases were assessed, Napsin-A was found not to have a
significant effect on survival.
A study suggested that NTRK-1 staining does not have
a significant effect on the prognosis of SqCC and AC but
is a positive prognostic factor for SqCC in patient survival
irrespective of sex, stage, age, and smoking (10). They

observed improvements in the disease-related survivals
of NTRK-2 positive SqCC cases but the effect of NTRK2 on survival in AC cases was statistically insignificant
(10). Contrasting this, we found that disease-free survival
time was significantly shorter in moderately NTRK-1
positive stained cases compared with mildly positive cases,
irrespective of the histological subtype and independent of
other variables. However, we observed that NTRK-2 did
not have any significant effect on the prognosis of SqCC
and we did not see any significant relationship between
NTRK-2 and TNM or lymph node metastasis.
In conclusion, we showed that Napsin-A, NTRK-2,
and Desmocollin-3 staining have statistically significant
meaning in detecting squamous cell carcinomas versus
adenocarcinomas. Desmoglein-3, Napsin-A, and NTRK-2
had no effect on prognosis but disease-free survival time
was significantly shorter in cases that were moderately
positively stained with NTRK-1.
We think that including Napsin-A, NTRK-2, and
Desmocollin-3 in the panel together with p63, TTF-1,
and mucin will improve differential diagnosis in cases of
“NSCC, not otherwise specified” that cannot be diagnosed
with available stains. However, larger studies are needed to
test this observation.
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